Edition:
United States

Avid Bioservices Inc (CDMO.OQ)

CDMO.OQ on NASDAQ Stock Exchange Capital Market

5.22USD
14 Dec 2018
Change (% chg)

$0.04 (+0.77%)
Prev Close
$5.18
Open
$5.17
Day's High
$5.42
Day's Low
$5.15
Volume
83,583
Avg. Vol
92,557
52-wk High
$8.40
52-wk Low
$2.25

Summary

Name Age Since Current Position

Roger Lias

2017 President, Chief Executive Officer

Daniel Hart

44 2018 Chief Financial Officer

Stephen Hedberg

43 2018 Chief Accounting Officer

Mark Ziebell

52 2012 Vice President, General Counsel, Corporate Secretary

Shelley Fussey

51 2005 Vice President - Intellectual Property

Magnus Schroeder

2018 Vice President - Process Sciences

Joseph Carleone

2017 Director

Richard Hancock

2017 Director

Joel McComb

2017 Director

Gregory Sargen

2017 Director

Mark Bamforth

52 2017 Independent Director

Patrick Walsh

57 2017 Independent Director

Biographies

Name Description

Roger Lias

Daniel Hart

Mr. Daniel Hart is Chief Financial Officer of the Company, effective August 1, 2018. Mr. Hart most recently served as Chief Financial Officer of ENO Holdings, Inc., a family of companies focused on the residential real estate market with offerings spanning brokerage, franchisor, property management, title and escrow services. While with ENO Holdings, he helped optimize the group’s accounting and finance department with a focus on establishing repeatable processes in the areas of financial statements, operating plans, cash forecasts and organization budgets. Prior to that position, Mr. Hart served as Senior Vice President, Chief Financial Officer and Assistant Secretary at SM&A, a $100 million private equity owned management consulting firm that was previously a Nasdaq-listed company. During his time at SM&A, which included several financial leadership positions of increasing responsibility, he was responsible for overseeing financial stewardship and played a central role in various financial transactions and corporate acquisitions. Mr. Hart also previously served as Corporate Controller for Biolase Technology, Inc., a Nasdaq-listed medical device manufacturer, helping the company complete a $52 million secondary offering and multiple corporate acquisitions. He earned a Bachelor of Science degree in accounting from California Polytechnic State University, San Luis Obispo.

Stephen Hedberg

Mr. Stephen Hedberg is Principal Accounting Officer of the Company. He has been employed by the Company since August 2000, and has served as its Senior Director of Finance and SEC Reporting since May 2010.

Mark Ziebell

Mr. Mark R. Ziebell is Vice President, General Counsel, Corporate Secretary of Peregrine Pharmaceuticals, Inc. He has been practicing corporate and securities law for over 20 years. Prior to joining us, Mr. Ziebell was a partner with the Costa Mesa, California office of Snell & Wilmer LLP where he worked from March 2004 to June 2012. Mr. Ziebell has represented public and private companies in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters and corporate governance. His experience involves a variety of industries, including biopharmaceutical and life sciences. Mr. Ziebell was our outside corporate counsel from 1999 to June 2012. Mr. Ziebell earned his B.S. in accounting in 1986 from the University of San Francisco and his Juris Doctorate in 1994 from the University of San Francisco School of Law. Prior to earning his law degree, Mr. Ziebell was a certified public accountant with BDO Seidman in San Francisco, California.

Shelley Fussey

Dr. Shelley P.M. Fussey, Ph.D., is Vice President - Intellectual Property of Peregrine Pharmaceuticals, Inc. Dr. Fussey plays a key role in our U.S. and international patenting, patent analysis and patent defense. Dr. Fussey’s expertise includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development. Prior to joining us, Dr. Fussey worked for the law firms of Williams, Morgan & Amerson and Arnold, White and Durkee. She holds a Ph.D. in Biochemistry and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University of Newcastle upon Tyne, U.K.

Magnus Schroeder

Mr. Magnus Schroeder is Vice President - Process Sciences of the Company. Dr. Schroeder most recently served as a director at AGC Biologics, formerly CMC Biologics, a global contract development and manufacturing organization, where he participated in the successful commercial launch of multiple products. In that role, he successfully supported more than 25 client projects as they progressed toward first-in-human clinical trials, commercial product launch and ongoing commercial supply. These efforts included creative resolution of complex challenges related to commercial processes that directly impacted a range of regulatory interactions and filings. In directing AGC's purification development team, Dr. Schroeder oversaw early-to-late phase development, process characterization, process control strategy, commercial process support and technology transfer/facility fit activities. Prior to AGC Biologics, Dr. Schroeder held multiple senior level positions with CSL Limited, a global leader in the field of biotechnology. During his tenure, he served as senior manager and senior scientist, leading process development activities for a range of CSL's innovative biologics. He has also held key process science positions with Dynavax Technologies, in which he was responsible for supporting process development, characterization and validation for multiple programs. Dr. Schroeder earned his Ph.D. in biochemical engineering and his master of science in molecular biotechnology from Bielefeld University in Bielefeld, Germany. He has previously served as a visiting scientist for protein purification at Rensselaer Polytechnic Institute and a visiting scientist for cell culture engineering at the University of Minnesota.

Joseph Carleone

Dr. Joseph Carleone, Ph.D., serves as Director of the Company. Dr. Carleone is Chairman of the Board of AMPAC Fine Chemicals LLC, a leading manufacturer of pharmaceutical active ingredients. Prior to this position, Dr. Carleone was President, Chief Executive Officer and director of American Pacific Corporation, a leading custom manufacturer of fine and specialty chemicals and propulsion products. Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Corporation. Dr. Carleone received his bachelor's degree in Mechanical Engineering from Drexel University, Philadelphia, Pennsylvania, in 1968; his master's degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel University in 1972.

Richard Hancock

Mr. Richard B. Hancock is Director of the Company. Richard B. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and CEO of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), and he is currently the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc., a CDMO focused on the biotechnology and life sciences industries. Mr. Hancock received a BA in Microbiology from Miami University.

Joel McComb

Mr. Joel McComb is Director of the Company. Joel McComb is the CEO, Chairman and Co-Founder of BioSpyder Technologies, Inc. Prior to BioSpyder, Mr. McComb served as Senior Vice President and General Manager of Illumina, Inc., President of GE Healthcare's Life Sciences and Discovery Systems division, and President of GE Healthcare's Interventional Medicine division. Prior to GE Healthcare, Mr. McComb was the President, CEO and a director of Innovadyne Technologies, Inc., and held various positions at Beckman Coulter, Inc., and Charles River Laboratories (at the time a division of Bausch & Lomb Inc.) where he was a National Business Manager for the company's monoclonal antibody CDMO division. Mr. McComb earned a Bachelor of Science degree in Genetics from the University of California, Davis and an MBA from Golden Gate University.

Gregory Sargen

Mr. Gregory P. Sargen is Director of the Company. Mr. Gregory P. Sargen currently serves as Executive Vice President – Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) ("Cambrex"), a global manufacturer and provider of services to life sciences companies. Prior to his current role, Mr. Sargen served as Executive Vice President and Chief Financial Officer of Cambrex. Prior to Cambrex, Mr. Sargen served as Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Ernst & Young LLP. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.

Mark Bamforth

Mr. Mark R. Bamforth is Independent Director of the Company. Prior to his founding of Brammer Bio and Gallus BioPharmaceuticals, Mr. Bamforth spent 22 years with Genzyme Corporation rising to the position of senior vice president of corporate operations and pharmaceuticals. In this role, he oversaw a multi-technology, global operations team comprised of more than 3,600 individuals at 13 internal sites and a network of 24 contract manufacturing organizations. This team was charged with supplying over 20 commercial products and multiple clinical products that spanned biologics, cell therapy, gene therapy, pharmaceuticals and biologic devices. While at Genzyme, Mr. Bamforth served as a member of the CEO's operating committee, helping to guide corporate strategy acquisition, partnering and growth to over $4 billion in sales. Mr. Bamforth also serves on the boards of MassBio and the Wentworth Institute of Technology, and is a Saltire Foundation founding-trustee. He earned a bachelor of science in chemical engineering from Strathclyde University and an MBA from Henley Management College.

Patrick Walsh

Mr. Patrick D. Walsh serves as Independent Director of the Company. Mr. Walsh currently serves as chief executive officer of Avista Pharma Solutions, a high-growth CDMO with over 220,000 square feet of facility space that provides pharmaceutical clients with a full suite of service offerings including analytical, microbiology, API, formulation, drug substance & drug product manufacturing expertise and capabilities. Prior to joining Avista Pharma, he was chief executive officer of AAIPharma Services, a private-equity backed CDMO at which he led a successful growth strategy culminating in the company's sale for more than 4.5 times return on invested capital. Mr. Walsh also held the positions of president and chief operating officer of Gensia-Sicor, during which time he led the company's commercial growth strategy, culminating in the eventual sale to Teva for $3.4 billion. Prior to Gensia, he spent 10 years in a global pharmaceutical company culminating in leading the U.S. and international business of a leading Japanese pharma company. Mr. Walsh has served on pharma boards as chairman, non-executive chairman and company director, as well as an executive advisor to private equity and venture capital firms. He currently serves on the board of Avista Pharma, which is backed by private-equity firm Ampersand Capital Partners.